Literature DB >> 14688483

Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.

A-C Goulet1, Janine G Einsphar, David S Alberts, Anthony Beas, Cynthia Burk, Achyut Bhattacharyya, Jerry Bangert, Janet M Harmon, Hideji Fujiwara, Alane Koki, Mark A Nelson.   

Abstract

Cyclooxygenase 2 (COX-2) is an inducible enzyme involved in the production of prostaglandins and thromboxanes during inflammation. There are now several lines of evidence indicating that increased expression of COX-2 plays a functional role in the development and progression of malignant epithelial cancers. However, there is only limited data regarding the role of COX-2 in melanoma pathogenesis. In the present work, we retrospectively examined lesions through out the development of melanoma and metastatic disease (dysplastic nevi n = 10, melanoma in situ n = 4, stage II melanoma n = 10, stage III n = 4, stage IV n = 3, stage V n = 2, melanoma metastasis lymph nodes n = 13 metastasis to other sites n = 3). COX-2 was consistently observed in keratinocytes, dermal fibroblasts, and inflammatory cells in regions adjacent to benign evi and primary cutaneous melanomas. However, no COX-2 staining was detected in the nevi nor in the primary skin melanoma cells. In addition, COX-2 was undetected in all vertical and radial growth phase cases Interestingly, 13 out of 13 of the lymph node metastasis expressed extremely high levels of COX-2 in overlying epithelium and inflammatory cells, and COX-2 was strongly detected in the metastatic cancer cells per se. For additional information on the expression of COX-2 in malignant melanoma, we determined the expression of COX-2 protein in several different melanoma cell lines. We found that 3We found that 5 out of 7 of the melanoma cells over expressed COX-2 compared to normal melanocytes. Collectively, these data suggest that COX-2 may play a functional role in metastases of melanoma, and treatment with COX-2 inhibitors may be efficacious for malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688483

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  33 in total

1.  TREM-1 is a positive regulator of TNF-α and IL-8 production in U937 foam cells.

Authors:  Yu-Shi Wang; Xiang-Jun Li; Wai-Ou Zhao
Journal:  Bosn J Basic Med Sci       Date:  2012-05       Impact factor: 3.363

Review 2.  Coffee consumption and the risk of cutaneous melanoma: a meta-analysis.

Authors:  Jia Wang; Xutong Li; Dongfeng Zhang
Journal:  Eur J Nutr       Date:  2015-12-22       Impact factor: 5.614

Review 3.  Cyclooxygenase- and lipoxygenase-mediated DNA damage.

Authors:  N Speed; I A Blair
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma.

Authors:  Daniel Y Wang; Jennifer L McQuade; Rajat R Rai; John J Park; Shilin Zhao; Fei Ye; Kathryn E Beckermann; Samuel M Rubinstein; Romany Johnpulle; Georgina V Long; Matteo S Carlino; Alexander M Menzies; Michael A Davies; Douglas B Johnson
Journal:  Oncologist       Date:  2019-11-29

Review 5.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

Review 6.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Prostaglandin-E2 is produced by adult human epidermal melanocytes in response to UVB in a melanogenesis-independent manner.

Authors:  Karl Gledhill; Lesley E Rhodes; Margaret Brownrigg; Ann K Haylett; Mojgan Masoodi; Anthony J Thody; Anna Nicolaou; Desmond J Tobin
Journal:  Pigment Cell Melanoma Res       Date:  2010-03-17       Impact factor: 4.693

8.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity.

Authors:  Mirna Balsamo; Francesca Scordamaglia; Gabriella Pietra; Claudia Manzini; Claudia Cantoni; Monica Boitano; Paola Queirolo; William Vermi; Fabio Facchetti; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari; Massimo Vitale
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

Review 9.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence.

Authors:  Maryam M Asgari; Sonia S Maruti; Emily White
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.